Therapeutic methods comprising the administration of 8-hydroxyquinoline-7-carboxylic acid or a pharmaceutically acceptable salt thereof and an antibacterial agent are disclosed. Also disclosed are combinations and kits comprising 8-hydroxyquinoline-7-carboxylic acid or a pharmaceutically acceptable salt thereof and an antibacterial agent.

This application relates to a pharmaceutical composition for anti-inflammation, including a probiotic and an antibiotic, and a method of preventing or treating inflammation by using the same. In one aspect, the method includes locally administrating a probiotic and an antibiotic to an inflamed area of a subject.

This application relates to a pharmaceutical composition for anti-inflammation, including a probiotic and an antibiotic, and a method of preventing or treating inflammation by using the same. In one aspect, the method includes locally administrating a probiotic and an antibiotic to an inflamed area of a subject.

The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease. In addition, the present methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion.

The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease. In addition, the present methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion.

The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease. In addition, the present methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion.

The present invention relates to an antibacterial peptide derived from Erythroculter ilishaeformis and use thereof. The amino acid sequence of the antibacterial peptide of the present invention includes an amino acid sequence as shown in SEQ ID NO: 1. The present invention further discloses use of the antibacterial peptide in the preparation of an anti-aquatic-bacterium drug for aquaculture animals. The present invention provides a novel antibacterial peptide, discloses a function of the novel antibacterial peptide for resisting aquatic bacteria, and provides candidate molecules for preventing and treating bacterial diseases in the culture process of Erythroculter ilishaeformis.

The present invention relates to an antibacterial peptide derived from Erythroculter ilishaeformis and use thereof. The amino acid sequence of the antibacterial peptide of the present invention includes an amino acid sequence as shown in SEQ ID NO: 1. The present invention further discloses use of the antibacterial peptide in the preparation of an anti-aquatic-bacterium drug for aquaculture animals. The present invention provides a novel antibacterial peptide, discloses a function of the novel antibacterial peptide for resisting aquatic bacteria, and provides candidate molecules for preventing and treating bacterial diseases in the culture process of Erythroculter ilishaeformis.

Methods of treating acute liver disease acute liver diseases are provided. Accordingly, there is provided a method of treating acute liver disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent capable of binding a component of a TLR-MYC signaling pathway selected from the group consisting of MYC, MYD88, TRIF and p38 and inhibiting expression and/or activity of the component.

Methods of treating acute liver disease acute liver diseases are provided. Accordingly, there is provided a method of treating acute liver disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent capable of binding a component of a TLR-MYC signaling pathway selected from the group consisting of MYC, MYD88, TRIF and p38 and inhibiting expression and/or activity of the component.